Diagnosis and treatment of drug-induced hyperthermia

American Journal of Health-System Pharmacy

Volumn 70, Issue 1, 2013, Pages 34-42

  Musselman, Megan E ^a   Saely, Suprat ^b  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; AMANTADINE; AMPHETAMINE DERIVATIVE; ATROPINE; BELLADONNA ALKALOID; BROMOCRIPTINE; CYPROHEPTADINE; DANTROLENE; DEXTROMETHORPHAN; DROPERIDOL; FENTANYL; HYPERICUM PERFORATUM EXTRACT; INHALATION ANESTHETIC AGENT; LEVODOPA; LINEZOLID; LITHIUM; LORAZEPAM; METOCLOPRAMIDE; MIDAZOLAM; NEUROLEPTIC AGENT; PETHIDINE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PROCHLORPERAZINE; PROMETHAZINE; SUMATRIPTAN; SUXAMETHONIUM; TRAMADOL; TRYPTOPHAN; UNINDEXED DRUG;

ANTICHOLINERGIC SYNDROME; BODY TEMPERATURE DISORDER; BRADYCARDIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG INDUCED HYPERTHERMIA; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HYPERTHERMIA; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MORBIDITY; MUSCLE WEAKNESS; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PHLEBITIS; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SYMPATHOMIMETIC POISONING; THERMOREGULATION;

EID: 84872318773     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110543     Document Type: Review

References (58)

1. Lefkowitz D, Ford CS, Rich C et al. Cerebellar syndrome following neuroleptic induced heat stroke. J Neurol Neurosurg Psychiatry. 1983; 46:183-5. (Pubitemid 13112108)
2. Kurz A. Physiology of thermoregulation. Best Pract Res Clin Anaesthesiol. 2008; 22:627-44.
3. Buggy DJ, Crossley AW. Thermoregulation, mild perioperative hypothermia and postanaesthetic shivering. Br J Anaesth. 2000; 84:615-28. (Pubitemid 30229604)
4. Diaz M, Becker DE. Thermoregulation: physiological and clinical considerations during sedation and general anesthesia. Anesth Prog. 2010; 57:25-32.
5. O'Grady NP, Barie PS, Bartlett J et al., for the Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Practice parameters for evaluating new fever in critically ill adult patients. Crit Care Med. 1998; 26:392-408.
6. Halloran LL, Bernard DW. Management of drug-induced hyperthermia. Curr Opin Pediatr. 2004; 16:211-5. (Pubitemid 38368362)
7. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010; 25:1780-90.
8. Pesola GR, Quinto C. Prochlorperazine-induced neuroleptic malignant syndrome. J Emerg Med. 1996; 14:727-9. (Pubitemid 27009223)
9. Manser TJ, Warner JF. Neuroleptic malignant syndrome associated with prochlorperazine. South Med J. 1990; 83:73-4. (Pubitemid 20049632)
10. Musselman ME, Browning LA, Parker D Jr et al. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. Ann Pharmacother. 2011; 45:e61.
11. Nonino F, Campomori A. Neuroleptic malignant syndrome associated with metoclopramide. Ann Pharmacother. 1999; 33:644-5. (Pubitemid 29255078)
12. Bakri YN, Khan R, Subhi J et al. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol. 1992; 44:189-90.
13. Nachreiner R, Balledux J, Zieger M et al. Neuroleptic malignant syndrome associated with metoclopramide in a burn patient. J Burn Care Res. 2006; 27:237-41. (Pubitemid 43970332)
14. Ratan DA, Smith AH. Neuroleptic malignant syndrome secondary to droperidol. Biol Psychiatry. 1993; 34:421-2. (Pubitemid 23295761)
15. So PC. Neuroleptic malignant syndrome induced by droperidol. Hong Kong Med J. 2001; 7:101-3. (Pubitemid 32769482)
16. Mendhekar DN, Andrade C. Neuroleptic malignant syndrome with promethazine. Aust N Z J Psychiatry. 2005; 39:310.
17. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J. 1999; 92:1017-8. (Pubitemid 29517018)
18. Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci. 1995; 7:135-44.
19. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 1999; 22:151-8.
20. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. 1991; 148:880-2.
21. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142:1137-45. (Pubitemid 16223648)
22. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50:18-25. (Pubitemid 19050611)
23. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999; 156:169-80. (Pubitemid 29077106)
24. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000.
25. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164:870-6. (Pubitemid 46972900)
26. Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother. 2007; 7:423-31. (Pubitemid 46623363)
27. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987; 22:1004-20. (Pubitemid 17095324)
28. Nisijima K, Noguti M, Ishiguro T. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry. 1997; 41:913-4. (Pubitemid 27158390)
29. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect. 1993; 92:57-65. (Pubitemid 23152951)
30. Sutin KM. Dantrolene sodium. In: Nelson L, Goldfrank LR, eds. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill Medical; 2010:1001-2.
31. Dantrolene sodium package insert. Rochester, MI: JHP Pharmaceuticals; 2008 Nov.
32. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982; 56:254-62.
33. McAllen KJ, Schwartz DR. Adverse drug reactions resulting in hyperthermia in the intensive care unit. Crit Care Med. 2010; 38:S244-52.
34. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's wort. J Psychopharmacol. 2002; 16:401. (Pubitemid 35470590)
35. Price WA, Zimmer B, Kucas P. Serotonin syndrome: a case report. J Clin Pharmacol. 1986; 26:77-8. (Pubitemid 16164526)
36. Isbister GK, Bowe SJ, Dawson A et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004; 42:277-85. (Pubitemid 39166756)
37. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112-20. [Errata, N Engl J Med. 2009; 361:1714, and N Engl J Med. 2007; 356:2437.]
38. Nisijima K, Shioda K, Yoshino T et al. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry. 2004; 37:57-62. (Pubitemid 38651018)
39. Done CJ, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 1994; 33:411-21.
40. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997; 13:763-83.
41. Dunkley EJ, Isbister GK, Sibbritt D et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003; 96:635-42. (Pubitemid 37063272)
42. Brvar M, Stajer D, Kozelj G et al. Urinary serotonin level is associated with serotonin syndrome after moclobemide, sertraline, and citalopram overdose. Clin Toxicol (Phila). 2007; 45:458-60. (Pubitemid 46763691)
43. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148:705-13.
44. Eyer F, Zilker T. Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. Crit Care. 2007; 11:236.
45. Kapur S, Zipursky RB, Jones C et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry. 1997; 154:884. (Pubitemid 27230123)
46. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999; 13:100-9. (Pubitemid 29141280)
47. Chan TC, Evans SD, Clark RF. Drug-induced hyperthermia. Crit Care Clin. 1997; 13:785-808. (Pubitemid 27432893)
48. Bronstein AC, Spyker DA, Cantilena LR Jr et al. 2009 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th annual report. Clin Toxicol (Phila). 2010; 48:979-1178.
49. Falk B, Dotan R. Children's thermoregulation during exercise in the heat: a revisit. Appl Physiol Nutr Metab. 2008; 33:420-7.
50. Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med. 2003; 10:149-54.
51. Howland MA. Physostigmine salicylate: antidote in depth (A12). In: Nelson L, Goldfrank LR, eds. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill Medical; 2010:759-62.
52. Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010; 12:435-42.
53. Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med. 1985; 14:1112-3. (Pubitemid 16201424)
54. Rosenberg H, Davis M, James D et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007; 2:21.
55. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985; 64:700-4. (Pubitemid 15064913)
56. Sambuughin N, Holley H, Muldoon S et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology. 2005; 102:515-21. (Pubitemid 40315139)
57. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol. 2001; 18:632-52. (Pubitemid 32939480)
58. Krause T, Gerbershagen MU, Fiege M et al. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004; 59:364-73. (Pubitemid 38489297)